Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer

Jing Wu, Wei-Kang Chen, Wei Zhang, Jin-Song Zhang, Jian-He Liu, Yong-Ming Jiang and Ke-Wei Fang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:59709-59719. https://doi.org/10.18632/oncotarget.19810

Metrics: PDF 1585 views  |   HTML 2875 views  |   ?  


Jing Wu1,*, Wei-Kang Chen2,*, Wei Zhang2, Jin-Song Zhang2, Jian-He Liu2, Yong-Ming Jiang2 and Ke-Wei Fang2

1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, Kunming 650500, P.R. China

2Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, P.R. China

*These authors contributed equally to this work

Correspondence to:

Ke-Wei Fang, email: [email protected]

Keywords: prostate cancer, endocrine therapy, efficacy, adverse effects, randomized controlled trials

Received: March 17, 2017     Accepted: July 25, 2017     Published: August 02, 2017


This network meta-analysis was conducted to compare the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer (PC). The PubMed and Cochrane Library databases were searched for randomized controlled trials of treatments for advanced/metastatic PC. Eighteen studies covering 6,340 patients were included in this analysis. The calculated were odds ratios, 95% confidence intervals, and the surface under the cumulative ranking (SUCRA) curve. Pairwise meta-analysis showed that overall survival rates achieved with radiotherapy or endocrine therapy were lower than obtained with radiotherapy + endocrine therapy. The endocrine therapy includes estrogen therapy, luteinizing hormone-releasing hormone agonist (LHRH-A), anti-androgen therapy (ADT), ADT + LHRH-A and estrogen therapy + LHRH-A, and its SUCRA values indicated that for overall response rate, estrogen therapy + LHRH-A ranked the highest (92.6%); for overall survival rate, ADT ranked the highest (75.2%); for anemia, estrogen therapy ranked the highest (88.2%); and for diarrhea and hot flushes, ADT ranked the highest (diarrhea, 87.4%; hot flushes, 89.3%). Cluster analysis on the endocrine therapy showed that ADT + LHRH-A achieved the highest overall survival and overall response rates in the treatment of advanced/metastatic PC. Estrogen therapy and ADT had the lowest incidences of diarrhea and anemia. Thus, combined radiotherapy + endocrine therapy had higher overall survival rate, and among the endocrine therapy, in terms of overall response rate and overall survival rate, ADT + LHRH-A may be a better regimen in the treatment of advanced or metastatic PC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19810